The process of providing oxygenated blood to the body's tissues is known as perfusion. Because they assist in replicating the function of the organ by pumping blood throughout the body, perfusion devices are frequently employed during organ transplant surgeries. Due to increased product releases by top market competitors and an increase in organ transplants, the global perfusion system market has lately enjoyed lucrative growth.
In the near future, it is anticipated that a key driver influencing the growth of the Perfusion System will be the increasing number of approvals and launches of new perfusion systems. In the near future, increased investment by significant market participants is also anticipated to fuel market expansion for perfusion systems globally. In addition, the growing requirement for organ transplants is anticipated to increase demand for perfusion systems and propel market expansion in the coming years.
Major Players in the Perfusion System Industry:
1. XVIVO Perfusion AB
XVIVO Perfusion AB was founded in 1998 and headquartered in Goteborg, Sweden. It has offices and research sites on three continents. MyCartis and XVIVO Perfusion AB announced their collaboration to develop a quick diagnostic tool to quickly evaluate the integrity of donated organs during ex-vivo perfusion in June 2019. Such a test can inform the transplant team and surgeon about the quality of an organ and the likelihood that the recipient will recover successfully.
2. Paragonix Technologies, Inc
Paragonix Technologies, Inc is a medical device company developing first-in class Organ Preservation and Transport Systems for optimum quality transplant organs. It was founded in 2010 and headquartered in Massachusetts, United States. The Company announced that it has raised $24 million in Series B funding, headed by Signet Healthcare Partners, in March 2023. The commercial reach of Paragonix Technologies, as well as its ongoing expansion of clinical service offerings and inventory expansion, will be strengthened by this growth investment, allowing the business to pursue transplant breakthroughs.
3. Organ Assist B.V.
Organ Assist B.V. was founded in 2005 and headquartered in The Netherlands. It has offices and research sites on three continents. XVIVO announced in September 2020 that it had entered into an agreement to acquire all shares of Organ Assist. The acquisition was conditional on XVIVO acquiring finance for the purchase price of up to EUR 24 million through a fresh share issuance, which the business successfully completed later that day.
